+

WO1996006604B1 - Procedes d'identification et de traitement de tumeurs resistantes - Google Patents

Procedes d'identification et de traitement de tumeurs resistantes

Info

Publication number
WO1996006604B1
WO1996006604B1 PCT/US1995/011125 US9511125W WO9606604B1 WO 1996006604 B1 WO1996006604 B1 WO 1996006604B1 US 9511125 W US9511125 W US 9511125W WO 9606604 B1 WO9606604 B1 WO 9606604B1
Authority
WO
WIPO (PCT)
Prior art keywords
mrp
use according
pages
compound
protein
Prior art date
Application number
PCT/US1995/011125
Other languages
English (en)
Other versions
WO1996006604A2 (fr
WO1996006604A3 (fr
Filing date
Publication date
Priority claimed from US08/298,644 external-priority patent/US5543428A/en
Priority claimed from DE19944432563 external-priority patent/DE4432563C2/de
Application filed filed Critical
Priority to JP8508977A priority Critical patent/JPH10505348A/ja
Priority to US08/793,659 priority patent/US6235785B1/en
Priority to AU35434/95A priority patent/AU3543495A/en
Priority to EP95932371A priority patent/EP0777472A2/fr
Publication of WO1996006604A2 publication Critical patent/WO1996006604A2/fr
Publication of WO1996006604A3 publication Critical patent/WO1996006604A3/fr
Publication of WO1996006604B1 publication Critical patent/WO1996006604B1/fr
Priority to US09/836,567 priority patent/US20020013370A1/en
Priority to US09/836,429 priority patent/US6673813B2/en

Links

Abstract

L'invention concerne un procédé d'identification et d'inversion de la résistance multiple aux anticancéreux d'une tumeur, qui consiste à administrer une certaine quantité de n'importe lequel des composés définis dans cette invention, cette quantité étant suffisante pour réaliser l'inversion de la résistance multiple aux anticancéreux.
PCT/US1995/011125 1994-08-31 1995-08-31 Procedes d'identification et de traitement de tumeurs resistantes WO1996006604A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP8508977A JPH10505348A (ja) 1994-08-31 1995-08-31 耐性腫瘍の同定および治療方法
US08/793,659 US6235785B1 (en) 1994-08-31 1995-08-31 Methods for identifying and treating resistant tumors
AU35434/95A AU3543495A (en) 1994-08-31 1995-08-31 Methods for identifying and treating resistant tumors
EP95932371A EP0777472A2 (fr) 1994-08-31 1995-08-31 Procedes d'identification et de traitement de tumeurs resistantes
US09/836,567 US20020013370A1 (en) 1994-08-31 2001-04-17 Methods for identifying and treating resistant tumors
US09/836,429 US6673813B2 (en) 1994-08-31 2001-04-17 Methods for identifying and treating resistant tumors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/298,644 1994-08-31
US08/298,644 US5543428A (en) 1994-08-31 1994-08-31 Method for treating resistant tumors
DE19944432563 DE4432563C2 (de) 1994-09-13 1994-09-13 Verwendung von amphiphilen Anionen zur Verminderung der Zytostatika-Resistenz durch Hemmung des durch das MRP-Protein vermittelten Membrantransports
DEP4432563.0 1994-09-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/793,659 Continuation-In-Part US6235785B1 (en) 1994-08-31 1995-08-31 Methods for identifying and treating resistant tumors

Publications (3)

Publication Number Publication Date
WO1996006604A2 WO1996006604A2 (fr) 1996-03-07
WO1996006604A3 WO1996006604A3 (fr) 1996-08-01
WO1996006604B1 true WO1996006604B1 (fr) 1996-09-12

Family

ID=25940080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011125 WO1996006604A2 (fr) 1994-08-31 1995-08-31 Procedes d'identification et de traitement de tumeurs resistantes

Country Status (6)

Country Link
US (3) US6235785B1 (fr)
EP (2) EP0777472A2 (fr)
JP (1) JPH10505348A (fr)
AU (1) AU3543495A (fr)
CA (1) CA2198752A1 (fr)
WO (1) WO1996006604A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006604A2 (fr) * 1994-08-31 1996-03-07 Eli Lilly And Company Procedes d'identification et de traitement de tumeurs resistantes
EP1115427B1 (fr) * 1998-09-25 2003-12-03 Horst Lindhofer Utilisation de cellules tumorales avec un decalage temporel en combinaison avec des anticorps intacts pour l'immunisation
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001085166A1 (fr) * 2000-05-09 2001-11-15 Creighton University Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses
JP2004513090A (ja) 2000-09-27 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
JP4350946B2 (ja) 2000-10-31 2009-10-28 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
MXPA03007394A (es) * 2001-02-20 2003-12-04 Bristol Myers Squibb Co Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
US10107437B2 (en) * 2015-09-15 2018-10-23 Mustang Sampling Llc Tooling friendly adapter for insertion probe access
WO2017095725A1 (fr) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Sulfonamides d'aryle utilisés en tant qu'antagonistes de blt1
WO2017095723A1 (fr) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
WO2017095722A1 (fr) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
US20190382363A1 (en) 2015-11-30 2019-12-19 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211791A (en) 1975-09-23 1980-07-08 Beecham Group Limited Indanediones
US4200577A (en) 1975-09-23 1980-04-29 Beecham Group Limited Coumarin derivatives
US4889871A (en) 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
US5216024A (en) 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5216172A (en) 1988-02-24 1993-06-01 Ajinomoto Co., Inc. 1,4-dihydropyridine-4-aryl-2,6-dimethyl-3,5-dicarboxylates useful as agents against drug resistant tumor cells
JPH02218654A (ja) * 1988-10-12 1990-08-31 Ono Pharmaceut Co Ltd 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤
ZA925185B (en) 1991-07-18 1993-04-29 Hoffmann La Roche Dithianes.
DK0544488T3 (da) * 1991-11-25 1998-04-06 Lilly Co Eli Substituerede phenylphenolleukotrienantagonister
PH30449A (en) 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
CA2129144C (fr) 1992-02-06 1999-07-13 Jules Freedman Renversement de la resistance a plus d'un medicament a l'aide de derives de triphenyle - azacycloalcane
DK0624090T3 (da) 1992-02-06 1996-11-11 Merrell Pharma Inc Ophævelse af multi-drug-resistens med tetraarylethylener
AU5162293A (en) 1992-09-17 1994-04-12 Board Of Trustees Of The University Of Illinois, The Methods for preventing multidrug resistance in cancer cells
IL107462A0 (en) * 1992-11-05 1994-02-27 Lilly Co Eli Drug resistance-conferring protein, antibodies reactive therewith and utilities thereof
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
EP0652004B1 (fr) 1993-10-15 2002-07-10 Eli Lilly And Company Méthode pour le traitement de néoplasmes résistants
US5543428A (en) 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors
WO1996006604A2 (fr) * 1994-08-31 1996-03-07 Eli Lilly And Company Procedes d'identification et de traitement de tumeurs resistantes

Similar Documents

Publication Publication Date Title
WO1996006604B1 (fr) Procedes d'identification et de traitement de tumeurs resistantes
Kohn et al. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates
Watson Antidepressant drugs as adjuvant analgesics
Ross et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer
US5166207A (en) Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
KR960008234B1 (ko) 신경중독손상을 감소시키기 위한 약제 조성물
Jordan et al. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
US20020128264A1 (en) Methods for treatment of conditions affected by activity of multidrug transporters
Reyes-Mugica et al. Loss of DCC expression and glioma progression
JP2000513009A (ja) カルシトニン擬似体
AU8906398A (en) A method of preventing or treating estrogen-dependent diseases and disorders
US20090202572A1 (en) Compositions and methods for modulating bone mass
KR960037675A (ko) 벤조니트릴 및 벤조플루오라이드
JP2002114680A (ja) 抗真菌剤
MA27197A1 (fr) Sels de tolterodine
AU650265B2 (en) Novel derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present
CA2465886A1 (fr) Procedes servant a favoriser l'absorption et l'accumulation nucleaire de polyamides dans des cellules eucaryotes
Goss et al. Haloperidol treatment increases D2 dopamine receptor protein independently of RNA levels in mice
US8501752B2 (en) Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines
Hwang et al. Interactions of sterols with antiestrogen-binding sites: structural requirements for high-affinity binding.
AU731125B2 (en) Method for inducing death of neoplastic cells using piperazine oxirane derivatives
Wardley FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA
US20220218660A1 (en) Composition for treating castration-resistant prostate cancer, comprising quassinoids
Nauta et al. Structure-activity relationships of H1-receptor antagonists
Boczkowski et al. Pattern of DNA replication of the sex chromosomes in three males, two with XYY and one with XXYY karyotype
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载